These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 24126432

  • 41. Neuroendocrine effects of naltrexone versus nalmefene in humans.
    Butelman ER, Fry RS, Kimani R, Reed B, Kreek MJ.
    Hum Psychopharmacol; 2020 Mar; 35(2):e2726. PubMed ID: 32050055
    [Abstract] [Full Text] [Related]

  • 42. Acute pulmonary edema in a young male after intravenous nalmefene.
    Henderson CA, Reynolds JE.
    Anesth Analg; 1997 Jan; 84(1):218-9. PubMed ID: 8989029
    [No Abstract] [Full Text] [Related]

  • 43. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
    Callaghan CK, Rouine J, Dean RL, Knapp BI, Bidlack JM, Deaver DR, O'Mara SM.
    Brain Behav Immun; 2018 Jan; 67():152-162. PubMed ID: 28844812
    [Abstract] [Full Text] [Related]

  • 44. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
    Dahmke H, Kupferschmidt H, Kullak-Ublick GA, Weiler S.
    Praxis (Bern 1994); 2015 Oct 14; 104(21):1129-34. PubMed ID: 26463904
    [Abstract] [Full Text] [Related]

  • 45. Vivitrex (Alkermes/Cephalon).
    Heading CE.
    Curr Opin Investig Drugs; 2006 Jan 14; 7(1):81-8. PubMed ID: 16425675
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Opioid antagonists for alcohol dependence.
    Srisurapanont M, Jarusuraisin N.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD001867. PubMed ID: 15674887
    [Abstract] [Full Text] [Related]

  • 53. [Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
    Favrelière S, Lafay-Chebassier C, Fauconneau B, Quillet A, Yéléhé-Okouma M, Montastruc F, Pérault-Pochat MC.
    Therapie; 2019 Jun 25; 74(3):369-374. PubMed ID: 30197228
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group.
    Eur Neuropsychopharmacol; 2013 Nov 25; 23(11):1432-42. PubMed ID: 23562264
    [Abstract] [Full Text] [Related]

  • 56. The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.
    Vollstädt-Klein S, Bumb JM, Otto A, Dinter C, Karl D, Koopmann A, Hermann D, Mann K, Kiefer F.
    Eur Neuropsychopharmacol; 2019 Dec 25; 29(12):1442-1452. PubMed ID: 31740271
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.